Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
阿利克松与阿斯利康罕见病宣布与泛加拿大药品联盟达成协议，以在治疗患有症状性、不可手术切除的神经纤维瘤类型1的小儿患者中使用科塞鲁戈。
Alexion, AstraZeneca Rare Disease Announces Agreement With Pan-Canadian Pharmaceutical Alliance For Koselugo In Treatment Of Paediatric Patients With Neurofibromatosis Type 1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
阿利克松与阿斯利康罕见病宣布与泛加拿大药品联盟达成协议，以在治疗患有症状性、不可手术切除的神经纤维瘤类型1的小儿患者中使用科塞鲁戈。
资讯热榜
更新时间